During the past decade, Little Rock Hematology Oncology Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Little Rock Hematology Oncology Associates" #1 sponsor was "Celgene" with 4 trials, followed by "Bristol-Myers Squibb" with 2 trials sponsored, "Telik" with 2 trials sponsored, "Accelerated Community Oncology Research Network" with 1 trials sponsored and "Eli Lilly and Company" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Little Rock Hematology Oncology Associates" #1 collaborator was "Genentech, Inc." with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Celgene Corporation" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "National Cancer Institute (NCI)" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Little Rock Hematology Oncology Associates" are "Breast Cancer" (2 trials), "Lung Cancer" (2 trials), "Ovarian Neoplasms" (2 trials), "Breast Neoplasms" (1 trials) and "Carcinoma, Non-Small-Cell Lung" (1 trials). Many other conditions were trialed in "Little Rock Hematology Oncology Associates" in a lesser frequency.

Most popular intervention types in "Little Rock Hematology Oncology Associates" are "Drug" (12 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "docetaxel" (2 trials), "paclitaxel" (2 trials), "ABI-007 (Abraxane)" (1 trials), "Abraxane" (1 trials) and "Albumin-bound paclitaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Little Rock Hematology Oncology Associates" are 9 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Little Rock Hematology Oncology Associates". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Little Rock Hematology Oncology Associates, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Little Rock Hematology Oncology Associates, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".